Home

arrow iconNewsarrow iconarrow icon

AiVA AI Assistant: IVI RMA Launches Fertility AI Platform

AiVA AI Assistant: IVI RMA Launches Fertility AI Platform

Flora Fertility and Clue have announced the Flora Clue fertility partnership, connecting the first individually owned fertility insurance platform with the world’s leading women-led cycle tracking app. FLORA policyholders receive complimentary Clue Plus access, while Clue’s community of over 100 million members gains early exposure to proactive fertility financial planning.

By FertilityIn

14 Oct 2026

1 min read

IVI RMA North America Logo

IVI RMA North America Logo

IVI RMA North America, a leader in fertility care and assisted reproduction, has unveiled the AiVA AI Assistant, a breakthrough AI capability built on Artemis, the organisation’s proprietary, fertility-specific technology platform. Together, Artemis and the AiVA AI Assistant represent the first comprehensive AI-powered clinical operating system designed from the ground up for reproductive medicine.


The platform is already live. Artemis is deployed across more than 60 clinics in North America, with approximately 2,000 users accessing it on a typical workday. IVI RMA has plans to extend it across its international network of more than 200 locations in 15 countries in the years ahead.


Why Artemis Was Built From Scratch

Existing healthcare technology platforms were not built for the specific complexity of fertility care. IVI RMA took a different approach, building Artemis entirely in-house to meet the operational and clinical demands of a large-scale reproductive medicine network and shaping it with direct input from fertility specialists across that network.


Dr. Thomas Molinaro, Chief Medical Officer of IVI RMA North America, explained the reasoning:


“Artemis was built from the ground up because no other technology platform could support the complexity of fertility care and give our teams the tools they need to deliver the high standard of care we are committed to provide throughout each patient’s treatment journey. AiVA AI Assistant establishes a new technology foundation for reproductive medicine — one that brings truly personalized care and can continuously evolve alongside our physicians, our care teams, and the patients we serve.”


Artemis is grounded in the reproductive medicine knowledge and longitudinal patient and clinical data accumulated across one of North America’s largest and most sophisticated fertility networks, a dataset that gives it a depth of contextual understanding that a general-purpose clinical platform cannot replicate.


What the AiVA AI Assistant Does

At the core of Artemis is the AiVA AI Assistant, whose capabilities are designed to solve problems that fertility clinicians encounter daily, fragmented patient data, administrative overload, inconsistent application of clinical protocols, and the limits of what any single physician can hold in mind at one time.


Key AiVA capabilities include

  • Network-wide clinical intelligence: Connects each patient’s chart to the collective expertise of more than 100 fertility specialists across the network, drawing on insights from hundreds of thousands of prior cases to identify patterns and inform personalised treatment decisions.
  • Anytime, anywhere access: Makes that intelligence available to physicians at any clinic in the network, so every patient can benefit from the organisation’s full body of knowledge, not just the knowledge of the physician in the room.
  • Rapid clinical synthesis: Transforms fragmented chart data, prior treatment cycles, laboratory results, embryology records, clinical notes, and outside records into a clear clinical picture in seconds, enabling faster and better-informed decisions.
  • Documentation support: Drafts chart-ready notes, patient messages, summaries, and follow-up plans in each clinician’s preferred format, reducing administrative burden and freeing time for patient care.
  • Embedded clinical workflows: Bring greater consistency to care by incorporating proven treatment logic, clinical protocols, and operational best practices into daily fertility medicine practice.

The Broader Artemis Platform

The AiVA AI Assistant sits within a larger suite of capabilities that together form what IVI RMA describes as a clinical operating system for fertility care.


  • Artemis Care Compass helps providers keep patients on track with their personalised treatment plans, proactively surfacing timely next steps to prevent care gaps.
  • AiVA Talk uses ambient AI to streamline clinical documentation in real time. The technology is estimated to save each physician between 35 and 110 minutes per day, depending on patient volume, creating additional capacity for direct patient engagement.
  • Artemis Messenger enables real-time communication between patients and care teams within the Artemis ecosystem. AI extracts and summarises documents, ensuring key information is captured, categorised, and available without requiring manual input from clinical staff.
  • Artemis Insights gives leadership a real-time view of clinical and operational trends to support decision-making at an organisational level.
  • Artemis Pulse Check goes a step further, using AI to give IVI RMA leadership near real-time insight into what matters most to patients, what is working well, and where the care experience can be improved. The platform then converts those insights into actionable recommendations spanning operations, finance, communications, and other areas.


The Team Behind the Platform

The Artemis platform was built and is maintained by a dedicated in-house engineering team. James DiLella, VP of Software Engineering and Global Head of New EHR at IVI RMA North America, described what the launch represents:


“A dedicated team of nearly 34 engineers has been building, testing, deploying, supporting, and maintaining Artemis’ suite of tools to effectively utilize AI across our clinics and labs. I couldn’t be prouder that we are finally pulling back the curtain on AiVA’s rollout across our U.S. network and the transformative effect this will have on our operations and on patient care.”


Lynn Mason, CEO of IVI RMA North America, framed the strategic significance of operating from a single platform across the network:


“Artemis is tangible proof of use of advanced technology to help deliver an exceptional experience for every patient, at every clinic. Operating from a single technology platform across our network gives us an extraordinary opportunity to share knowledge, learn from our patients, and continuously strengthen how we deliver care and strengthen the patient experience across our network.”

1 views

Share

FertilityIn

Send Enquiry for this Story

Previous News

UK’s First Testicular Tissue Transplant Offers Hope for Fertility Preservation

Next News

WHO Issues First Global Guideline on Infertility Care

Related Articles

UK’s First Testicular Tissue Transplant Offers Hope for Fertility Preservation

UK’s First Testicular Tissue Transplant Offers Hope for Fertility Preservation

Doctors at NHS Lothian in Edinburgh have performed the UK’s first testicular tissue transplant, reimplanting tissue frozen before chemotherapy in a 19-year-old patient with a serious blood disorder. The testicular tissue transplant, only the second reported worldwide, could eventually give thousands of young boys a realistic path to future fatherhood.

ART

1 min read

WHO Issues First Global Guideline on Infertility Care

WHO Issues First Global Guideline on Infertility Care

The World Health Organization releases its first comprehensive, evidence-based global guideline for infertility prevention, diagnosis, and treatment. Addressing one in six people of reproductive age worldwide, the guideline emphasizes equity, human rights, and standardized interventions to improve access to fertility care globally.

ART

1 min read

Gameto Secures $44M Series C as Stem Cell Fertility Therapy Advances to Phase 3 Trial

Gameto Secures $44M Series C as Stem Cell Fertility Therapy Advances to Phase 3 Trial

Gameto has secured $44 million in Series C funding to advance its stem cell-derived fertility therapy, Fertilo, into Phase 3 trials, marking a significant milestone in reproductive healthcare. This groundbreaking therapy uses induced pluripotent stem cell technology to mature eggs outside the body, significantly reducing hormonal stimulation and enhancing safety and efficacy in fertility treatments.

ART

1 min read

INVO Fertility Partners with Heidi Health to Bring AI Tools to Wisconsin Institute

INVO Fertility Partners with Heidi Health to Bring AI Tools to Wisconsin Institute

INVO Fertility partners with Heidi Health to integrate an AI-powered scribe at Wisconsin Fertility Institute, streamlining documentation so clinicians focus on care.

ART

1 min read

IVI RMA Adds Middle East Operating Region as ART Fertility Joins its Global Care Network

IVI RMA Adds Middle East Operating Region as ART Fertility Joins its Global Care Network

With ART Fertility Clinics now part of its network, IVI RMA Global has created a Middle East operating region to meet growing fertility needs. The integration boosts treatment capacity, scientific output, and care consistency across the UAE and Saudi Arabia as demographic pressures shape demand for assisted reproduction

ART

1 min read

California SB 729  Expands Insured Large Employers Coverage of Infertility and IVF from 2026

California SB 729 Expands Insured Large Employers Coverage of Infertility and IVF from 2026

California SB 729 now requires insured large employers to provide comprehensive coverage for infertility and IVF starting from 2026, significantly increasing workplace benefits.

ART

1 min read

Landing Page Image

Subscribe to our Newsletter

Stay updated with the latest news, expert insights, and exclusive offers delivered straight to your inbox. Join our community today!

Email Address